Identification of Toll-Like Receptor 3 as a Potential Therapeutic Target in Clear Cell Renal Cell Carcinoma

Purpose: Renal cell carcinoma (RCC) is one of the most drug-refractory cancers. The aim of this study is to discover a novel therapeutic target molecule for clear cell RCC (CCRCC), which accounts for the majority of RCC. Experimental Design: Gene expression profiles of 27 CCRCCs and 9 normal kidney tissues as well as 15 various adult normal tissues were examined by Affymetrix U133 Plus 2.0 arrays. Among the 34 genes specifically up-regulated in CCRCC, overexpression of Toll-like receptor 3 (TLR3) mRNA and its protein was validated by quantitative reverse transcription-PCR, immunoblot, and immunohistochemistry. The effects of TLR3 signaling on in vitro cell growth were examined. Results:TLR3 gene was highly expressed in CCRCC, with only limited expression in a panel of normal tissues. On immunohistochemical analysis using a monoclonal antibody against TLR3, overexpression of TLR3 was observed in 139 of 189 (73.5%) cases of CCRCC as well as in lung metastatic CCRCC (6 of 8), whereas TLR3 expression was entirely absent in chromophobe RCC (0 of 8). Polyinosinic-polycytidilic acid, a TLR3 ligand, exerted a growth-inhibitory effect against RCC cells in a TLR3-dependent manner. Moreover, a combination of polyinosinic-polycytidilic acid and IFNα exerted a synergistic growth-inhibitory effect against Caki-1 RCC cells. Conclusions: This is the first report that TLR3 is overexpressed in CCRCC. These observations suggest that TLR3 pathway may represent a novel therapeutic target in CCRCC.

[1]  H. Lillehoj,et al.  Lymphocyte Proliferation Response During Eimeria tenella Infection Assessed by a New, Reliable, Nonradioactive Colorimetric Assay , 2002, Avian diseases.

[2]  M. Mizuno,et al.  Significant antitumoral activity of cationic multilamellar liposomes containing human IFN-beta gene against human renal cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  M. Atkins,et al.  Systemic therapy for renal cell carcinoma. , 2005, Cancer chemotherapy and biological response modifiers.

[4]  Hui Wang,et al.  Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: Effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy , 2006, The Prostate.

[5]  R. Oliver,et al.  Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. , 1989, British journal of urology.

[6]  R. Bumsted,et al.  Case Report and Literature Review , 1980 .

[7]  J L Warren,et al.  Rising incidence of renal cell cancer in the United States. , 1999, JAMA.

[8]  J. Heesemann,et al.  Signaling of Apoptosis through TLRs Critically Involves Toll/IL-1 Receptor Domain-Containing Adapter Inducing IFN-β, but Not MyD88, in Bacteria-Infected Murine Macrophages1 , 2004, The Journal of Immunology.

[9]  D. Grandér,et al.  Why do so many cancer patients fail to respond to interferon therapy? , 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[10]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[11]  L. Sobin,et al.  TNM staging of renal cell carcinoma , 1997, Cancer.

[12]  Yibang Chen,et al.  Toll-like receptors on tumor cells facilitate evasion of immune surveillance. , 2005, Cancer research.

[13]  M. Mason,et al.  The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. , 2005, Vaccine.

[14]  E. Rosenthal,et al.  Toll-Like Receptor 9 Agonists Promote Cellular Invasion by Increasing Matrix Metalloproteinase Activity , 2006, Molecular Cancer Research.

[15]  D. Schwartz.  Union Internationale Contre le Cancer (UICC) , 2005 .

[16]  J. Tschopp,et al.  Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. , 2006, Molecular cell.

[17]  H Aburatani,et al.  Direct comparison of GeneChip and SAGE on the quantitative accuracy in transcript profiling analysis. , 2000, Genomics.

[18]  A. Iwasaki,et al.  Toll-like receptor control of the adaptive immune responses , 2004, Nature Immunology.

[19]  R. Schilsky,et al.  Cancer and Leukemia Group B 90206 , 2004, Clinical Cancer Research.

[20]  B. Delahunt,et al.  Classification of renal cell carcinoma , 1997, Cancer.

[21]  D. Weissman,et al.  mRNA Is an Endogenous Ligand for Toll-like Receptor 3* , 2004, Journal of Biological Chemistry.

[22]  O. Iliopoulos.  Molecular biology of renal cell cancer and the identification of therapeutic targets. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Salmon,et al.  Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. , 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[24]  J. Wang,et al.  Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword? , 2006, British Journal of Cancer.

[25]  M. Mizuno,et al.  lnterferon‐β gene therapy for cancer: Basic research to clinical application , 2004 .

[26]  S. Lebecque,et al.  TLR3 Can Directly Trigger Apoptosis in Human Cancer Cells1 , 2006, The Journal of Immunology.

[27]  W. Marston Linehan,et al.  Genetic Basis of Cancer of the Kidney , 2004, Clinical Cancer Research.

[28]  E. Jonasch,et al.  Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. , 2001, The oncologist.

[29]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[30]  L. Sobin,et al.  Union Internationale Contre le Cancer (UICC) and the American Joint TNM Staging of Renal Cell Committee on Cancer (AJCC) Carcinoma , 1997 .

[31]  J. Lokich.  Spontaneous regression of metastatic renal cancer. Case report and literature review. , 1997, American journal of clinical oncology.

[32]  A. Krieg,et al.  Therapeutic potential of Toll-like receptor 9 activation , 2006, Nature Reviews Drug Discovery.

[33]  T. Shows,et al.  Transcriptional regulation of TSG6, a tumor necrosis factor- and interleukin-1-inducible primary response gene coding for a secreted hyaluronan-binding protein. , 1993, The Journal of biological chemistry.

[34]  H. Aburatani,et al.  An opposing view on WWOX protein function as a tumor suppressor. , 2003, Cancer research.

[35]  C. Schmidt.  Immune system's Toll-like receptors have good opportunity for cancer treatment. , 2006, Journal of the National Cancer Institute.

[36]  A. Dejean,et al.  Molecular Cloning of a New Interferon-induced PML Nuclear Body-associated Protein* , 1997, The Journal of Biological Chemistry.

[37]  E. Bock,et al.  Novel role of toll-like receptor 3 in hepatitis C-associated glomerulonephritis. , 2006, The American journal of pathology.

[38]  H. Aburatani,et al.  Identification of ROBO1 as a Novel Hepatocellular Carcinoma Antigen and a Potential Therapeutic and Diagnostic Target , 2006, Clinical Cancer Research.

[39]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[40]  K. Marumo,et al.  The prevalence of renal cell carcinoma: A nation‐wide survey in Japan in 1997 , 2001, International journal of urology : official journal of the Japanese Urological Association.

[41]  J. Cheville,et al.  Comparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma , 2003, The American journal of surgical pathology.

[42]  A. Yamamoto,et al.  Subcellular Localization of Toll-Like Receptor 3 in Human Dendritic Cells 1 , 2003, The Journal of Immunology.

[43]  S. Fawell,et al.  Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  E. De Clercq,et al.  Increased susceptibility of cells treated with interferon to the toxicity of polyriboinosinic-polyribocytidylic acid. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Flavell,et al.  Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.